|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scholz HS, Tasdemir H, Hunlich T, Turnwald
W, Both A and Egger H: Multivisceral cytoreductive surgery in FIGO
stages IIIC and IV epithelial ovarian cancer: Results and 5-year
follow-up. Gynecol Oncol. 106:591–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wei W, Ji X, Guo X and Ji S: Regulatory
role of N6 -methyladenosine (m6 A) methylation in RNA processing
and human diseases. J Cell Biochem. 118:2534–2543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han
D, Fu Y, Parisien M, Dai Q, Jia G, et al:
N-6-methyladenosine-dependent regulation of messenger RNA
stability. Nature. 505:117–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin S and Gregory RI: Methyltransferases
modulate RNA stability in embryonic stem cells. Nat Cell Biol.
16:129–131. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartz S, Mumbach MR, Jovanovic M, Wang
T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N,
Cacchiarelli D, et al: Perturbation of m6A writers reveals two
distinct classes of mRNA methylation at internal and 5 sites. Cell
Rep. 8:284–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin S, Choe J, Du P, Triboulet R and
Gregory RI: The m(6)A methyltransferase METTL3 promotes translation
in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vu LP, Pickering BF, Cheng Y, et al: The
N-6-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid
differentiation of normal hematopoietic and leukemia cells. Nat
Med. 23:1369–1376. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Tang J, Huang W, Wang F, Li P, Qin
C, Qin Z, Zou Q, Wei J, Hua L, et al: The M6A methyltransferase
METTL3: Acting as a tumor suppressor in renal cell carcinoma.
Oncotarget. 8:96103–96116. 2017.PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroeger PT Jr and Drapkin R: Pathogenesis
and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yi X, Yin XM and Dong Z: Inhibition of
Bid-induced apoptosis by Bcl-2. tBid insertion, Bax translocation,
and Bax/Bak oligomerization suppressed. J Biol Chem.
278:16992–16999. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radha G and Raghavan SC: BCL2: A promising
cancer therapeutic target. Biochimica et Biophysica Acta (BBA). Rev
Can. 1868:309–314. 2017.
|
|
14
|
Chen M, Wei L, Law C-T, et al: RNA
N6-methyladenosine methyltransferase-like 3 promotes liver cancer
progression through YTHDF2-dependent posttranscriptional silencing
of SOCS2. Hepatology. 67:2254–2270. 2017. View Article : Google Scholar
|
|
15
|
Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue
Q, Wang D, Huang J, Gao S and Gao Y: MiR-33a suppresses
proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem
Biophys Res Commun. 482:582–589. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang
Z, Liu Y, Zhang X, Zhang W and Ye L: HBXIP-elevated
methyltransferase METTL3 promotes the progression of breast cancer
via inhibiting tumor suppressor let-7g. Cancer Lett. 415:11–19.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
